4D Molecular Therapeutics, Inc.
NASDAQFDMT upgraded to Overweight by Cantor Fitzgerald with $20 price target, up from prior Neutral rating.
Snapshot as of 21 Sept 2026
4D Molecular Therapeutics reports today with short sellers holding a meaningful position — but the borrow market suggests conviction is limited rather than extreme. Short interest runs at roughly 20.5% of the free…
4D Molecular Therapeutics reports Q1 results today with short sellers holding one of the heaviest positions in the biotech space. Short interest has climbed sharply into the print. At 20.7% of the free float — up 18%…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for FDMT — free to start on ORTEX.
Sign up for free →Open FDMT on ORTEX